Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kerry Setchfield is active.

Publication


Featured researches published by Kerry Setchfield.


American Journal of Human Genetics | 2012

Contribution of global rare copy-number variants to the risk of sporadic congenital heart disease.

Rachel Soemedi; Ian Wilson; Jamie Bentham; Rebecca Darlay; Ana Töpf; Diana Zelenika; Catherine Cosgrove; Kerry Setchfield; Chris Thornborough; Javier Granados-Riveron; Gillian M. Blue; Jeroen Breckpot; Stephen Hellens; Simon Zwolinkski; Elise Glen; Chrysovalanto Mamasoula; Thahira Rahman; Darroch Hall; Anita Rauch; Koenraad Devriendt; Marc Gewillig; John O’Sullivan; David S. Winlaw; Frances A. Bu’Lock; J. David Brook; Shoumo Bhattacharya; Mark Lathrop; Mauro Santibanez-Koref; Heather J. Cordell; Judith A. Goodship

Previous studies have shown that copy-number variants (CNVs) contribute to the risk of complex developmental phenotypes. However, the contribution of global CNV burden to the risk of sporadic congenital heart disease (CHD) remains incompletely defined. We generated genome-wide CNV data by using Illumina 660W-Quad SNP arrays in 2,256 individuals with CHD, 283 trio CHD-affected families, and 1,538 controls. We found association of rare genic deletions with CHD risk (odds ratio [OR] = 1.8, p = 0.0008). Rare deletions in study participants with CHD had higher gene content (p = 0.001) with higher haploinsufficiency scores (p = 0.03) than they did in controls, and they were enriched with Wnt-signaling genes (p = 1 × 10(-5)). Recurrent 15q11.2 deletions were associated with CHD risk (OR = 8.2, p = 0.02). Rare de novo CNVs were observed in ~5% of CHD trios; 10 out of 11 occurred on the paternally transmitted chromosome (p = 0.01). Some of the rare de novo CNVs spanned genes known to be involved in heart development (e.g., HAND2 and GJA5). Rare genic deletions contribute ~4% of the population-attributable risk of sporadic CHD. Second to previously described CNVs at 1q21.1, deletions at 15q11.2 and those implicating Wnt signaling are the most significant contributors to the risk of sporadic CHD. Rare de novo CNVs identified in CHD trios exhibit paternal origin bias.


Human Molecular Genetics | 2012

Phenotype-specific effect of chromosome 1q21.1 rearrangements and GJA5 duplications in 2436 congenital heart disease patients and 6760 controls

Rachel Soemedi; Ana Töpf; Ian Wilson; Rebecca Darlay; Thahira Rahman; Elise Glen; Darroch Hall; Ni Huang; Jamie Bentham; Shoumo Bhattacharya; Catherine Cosgrove; J. David Brook; Javier Granados-Riveron; Kerry Setchfield; Frances Bu'Lock; Chris Thornborough; Koenraad Devriendt; Jeroen Breckpot; Michael Hofbeck; Mark Lathrop; Anita Rauch; Gillian M. Blue; David S. Winlaw; Mauro Santibanez-Koref; Heather J. Cordell; Judith A. Goodship; Bernard Keavney

Recurrent rearrangements of chromosome 1q21.1 that occur via non-allelic homologous recombination have been associated with variable phenotypes exhibiting incomplete penetrance, including congenital heart disease (CHD). However, the gene or genes within the ∼1 Mb critical region responsible for each of the associated phenotypes remains unknown. We examined the 1q21.1 locus in 948 patients with tetralogy of Fallot (TOF), 1488 patients with other forms of CHD and 6760 ethnically matched controls using single nucleotide polymorphism genotyping arrays (Illumina 660W and Affymetrix 6.0) and multiplex ligation-dependent probe amplification. We found that duplication of 1q21.1 was more common in cases of TOF than in controls [odds ratio (OR) 30.9, 95% confidence interval (CI) 8.9–107.6); P = 2.2 × 10−7], but deletion was not. In contrast, deletion of 1q21.1 was more common in cases of non-TOF CHD than in controls [OR 5.5 (95% CI 1.4–22.0); P = 0.04] while duplication was not. We also detected rare (n = 3) 100–200 kb duplications within the critical region of 1q21.1 in cases of TOF. These small duplications encompassed a single gene in common, GJA5, and were enriched in cases of TOF in comparison to controls [OR = 10.7 (95% CI 1.8–64.3), P = 0.01]. These findings show that duplication and deletion at chromosome 1q21.1 exhibit a degree of phenotypic specificity in CHD, and implicate GJA5 as the gene responsible for the CHD phenotypes observed with copy number imbalances at this locus.


Nature Genetics | 2013

Genome-wide association study of multiple congenital heart disease phenotypes identifies a susceptibility locus for atrial septal defect at chromosome 4p16.

Heather J. Cordell; Jamie Bentham; Ana Töpf; Diana Zelenika; Simon Heath; Chrysovalanto Mamasoula; Catherine Cosgrove; Gillian M. Blue; Javier Granados-Riveron; Kerry Setchfield; Chris Thornborough; Jeroen Breckpot; Rachel Soemedi; Ruairidh Martin; Thahira Rahman; Darroch Hall; Klaartje van Engelen; Antoon F. M. Moorman; Aelko H. Zwinderman; Phil Barnett; Tamara T. Koopmann; Michiel E. Adriaens; András Varró; Alfred L. George; Christobal Dos Remedios; Nanette H. Bishopric; Connie R. Bezzina; John O'Sullivan; Marc Gewillig; Frances Bu'Lock

We carried out a genome-wide association study (GWAS) of congenital heart disease (CHD). Our discovery cohort comprised 1,995 CHD cases and 5,159 controls and included affected individuals from each of the 3 major clinical CHD categories (with septal, obstructive and cyanotic defects). When all CHD phenotypes were considered together, no region achieved genome-wide significant association. However, a region on chromosome 4p16, adjacent to the MSX1 and STX18 genes, was associated (P = 9.5 × 10−7) with the risk of ostium secundum atrial septal defect (ASD) in the discovery cohort (N = 340 cases), and this association was replicated in a further 417 ASD cases and 2,520 controls (replication P = 5.0 × 10−5; odds ratio (OR) in replication cohort = 1.40, 95% confidence interval (CI) = 1.19–1.65; combined P = 2.6 × 10−10). Genotype accounted for ∼9% of the population-attributable risk of ASD.


Congenital Heart Disease | 2012

Combined Mutation Screening of NKX2-5, GATA4, and TBX5 in Congenital Heart Disease: Multiple Heterozygosity and Novel Mutations

Javier Granados-Riveron; Mark Pope; Frances Bu'Lock; Christopher Thornborough; Jacqueline Eason; Kerry Setchfield; Ami Ketley; Edwin P. Kirk; Diane Fatkin; Michael P. Feneley; Richard P. Harvey; J. David Brook

Background Variants of several genes encoding transcription modulators, signal transduction, and structural proteins are known to cause Mendelian congenital heart disease (CHD). NKX2-5 and GATA4 were the first CHD-causing genes identified by linkage analysis in large affected families. Mutations of TBX5 cause Holt–Oram syndrome, which includes CHD as a clinical feature. All three genes have a well-established role in cardiac development. Design In order to investigate the possible role of multiple mutations in CHD, a combined mutation screening was performed in NKX2-5, GATA4, and TBX5 in the same patient cohort. Samples from a cohort of 331 CHD patients were analyzed by polymerase chain reaction, double high-performance liquid chromatography and sequencing in order to identify changes in the NKX2-5, GATA4, and TBX5 genes. Results Two cases of multiple heterozygosity of putative disease-causing mutations were identified. One patient was found with a novel L122P NKX2-5 mutation in combination with the private A1443D mutation of MYH6. A patient heterozygote for a D425N GATA4 mutation carries also a private mutation of the MYH6 gene (V700M). Conclusions In addition to reporting two novel mutations of NKX2-5 in CHD, we describe families where multiple individual mutations seem to have an additive effect over the pathogenesis of CHD. Our findings highlight the usefulness of multiple gene mutational analysis of large CHD cohorts.


Human Molecular Genetics | 2013

Genome-wide association study identifies loci on 12q24 and 13q32 associated with Tetralogy of Fallot

Heather J. Cordell; Ana Töpf; Chrysovalanto Mamasoula; Alex V. Postma; Jamie Bentham; Diana Zelenika; Simon Heath; Gillian M. Blue; Catherine Cosgrove; Javier Granados Riveron; Rebecca Darlay; Rachel Soemedi; Ian Wilson; Kristin L. Ayers; Thahira Rahman; Darroch Hall; Barbara J.M. Mulder; Aelko H. Zwinderman; Klaartje van Engelen; J. David Brook; Kerry Setchfield; Frances Bu'Lock; Chris Thornborough; John O'Sullivan; A. Graham Stuart; Jonathan M. Parsons; Shoumo Bhattacharya; David S. Winlaw; Seema Mital; Marc Gewillig

We conducted a genome-wide association study to search for risk alleles associated with Tetralogy of Fallot (TOF), using a northern European discovery set of 835 cases and 5159 controls. A region on chromosome 12q24 was associated (P = 1.4 × 10−7) and replicated convincingly (P = 3.9 × 10−5) in 798 cases and 2931 controls [per allele odds ratio (OR) = 1.27 in replication cohort, P = 7.7 × 10−11 in combined populations]. Single nucleotide polymorphisms in the glypican 5 gene on chromosome 13q32 were also associated (P = 1.7 × 10−7) and replicated convincingly (P = 1.2 × 10−5) in 789 cases and 2927 controls (per allele OR = 1.31 in replication cohort, P = 3.03 × 10−11 in combined populations). Four additional regions on chromosomes 10, 15 and 16 showed suggestive association accompanied by nominal replication. This study, the first genome-wide association study of a congenital heart malformation phenotype, provides evidence that common genetic variation influences the risk of TOF.


Circulation-cardiovascular Genetics | 2013

Association between C677T polymorphism of methylene tetrahydrofolate reductase and congenital heart disease: meta-analysis of 7697 cases and 13,125 controls.

Chrysovalanto Mamasoula; R. Reid Prentice; Tomasz Pierscionek; Faith Pangilinan; James L. Mills; Charlotte M. Druschel; Kenneth A. Pass; Mark W. Russell; Darroch Hall; Ana Töpf; Danielle L. Brown; Diana Zelenika; Jamie Bentham; Catherine Cosgrove; Shoumo Bhattacharya; Javier Granados Riveron; Kerry Setchfield; J. David Brook; Frances Bu'Lock; Chris Thornborough; Thahira Rahman; Julian Palomino Doza; Huay Lin Tan; John O'Sullivan; A. Graham Stuart; Gillian M. Blue; David S. Winlaw; Alex V. Postma; Barbara J.M. Mulder; Aelko H. Zwinderman

Background—Association between the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and congenital heart disease (CHD) is contentious. Methods and Results—We compared genotypes between CHD cases and controls and between mothers of CHD cases and controls. We placed our results in context by conducting meta-analyses of previously published studies. Among 5814 cases with primary genotype data and 10 056 controls, there was no evidence of association between MTHFR C677T genotype and CHD risk (odds ratio [OR], 0.96 [95% confidence interval, 0.87–1.07]). A random-effects meta-analysis of all studies (involving 7697 cases and 13 125 controls) suggested the presence of association (OR, 1.25 [95% confidence interval, 1.03–1.51]; P=0.022) but with substantial heterogeneity among contributing studies (I2=64.4%) and evidence of publication bias. Meta-analysis of large studies only (defined by a variance of the log OR <0.05), which together contributed 83% of all cases, yielded no evidence of association (OR, 0.97 [95% confidence interval, 0.91–1.03]) without significant heterogeneity (I2=0). Moreover, meta-analysis of 1781 mothers of CHD cases (829 of whom were genotyped in this study) and 19 861 controls revealed no evidence of association between maternal C677T genotype and risk of CHD in offspring (OR, 1.13 [95% confidence interval, 0.87–1.47]). There was no significant association between MTHFR genotype and CHD risk in large studies from regions with different levels of dietary folate. Conclusions—The MTHFR C677T polymorphism, which directly influences plasma folate levels, is not associated with CHD risk. Publication biases appear to substantially contaminate the literature with regard to this genetic association.


Journal of Molecular and Cellular Cardiology | 2017

Tropomyosin 1: Multiple roles in the developing heart and in the formation of congenital heart defects

Jennifer England; Javier Granados-Riveron; Luis Polo-Parada; Diji Kuriakose; Christopher J. Moore; J. David Brook; Catrin S. Rutland; Kerry Setchfield; Christopher Gell; Tushar K. Ghosh; Frances Bu'Lock; Christopher Thornborough; Elisabeth Ehler; Siobhan Loughna

Tropomyosin 1 (TPM1) is an essential sarcomeric component, stabilising the thin filament and facilitating actins interaction with myosin. A number of sarcomeric proteins, such as alpha myosin heavy chain, play crucial roles in cardiac development. Mutations in these genes have been linked to congenital heart defects (CHDs), occurring in approximately 1 in 145 live births. To date, TPM1 has not been associated with isolated CHDs. Analysis of 380 CHD cases revealed three novel mutations in the TPM1 gene; IVS1 + 2T > C, I130V, S229F and a polyadenylation signal site variant GATAAA/AATAAA. Analysis of IVS1 + 2T > C revealed aberrant pre-mRNA splicing. In addition, abnormal structural properties were found in hearts transfected with TPM1 carrying I130V and S229F mutations. Phenotypic analysis of TPM1 morpholino-treated embryos revealed roles for TPM1 in cardiac looping, atrial septation and ventricular trabeculae formation and increased apoptosis was seen within the heart. In addition, sarcomere assembly was affected and altered action potentials were exhibited. This study demonstrated that sarcomeric TPM1 plays vital roles in cardiogenesis and is a suitable candidate gene for screening individuals with isolated CHDs.


bioRxiv | 2018

Deleterious genetic variants in NOTCH1 are a major contributor to the incidence of non-syndromic Tetralogy of Fallot

Donna J Page; Matthieu J. Miossec; Simon G Williams; Elisavet Fotiou; Richard M. Monaghan; Heather J Cordell; Louise Sutcliffe; Ana Töpf; Mathieu Bourgey; Guillaume Bourque; Robert Eveleigh; Sally L. Dunwoodie; David S. Winlaw; Shoumo Bhattacharya; Jeroen Breckpot; Koenraad Devriendt; Marc Gewillig; David Brook; Kerry Setchfield; Frances Bu'Lock; John O'Sullivan; Graham Stuart; Connie R. Bezzina; Barbara J.M. Mulder; Alex V. Postma; James R Bentham; Martin Baron; Sanjeev Bhaskar; Graeme C.M. Black; William G. Newman

Aims Familial recurrence studies provide strong evidence for a genetic component to the predisposition to sporadic, non-syndromic Tetralogy of Fallot (TOF), the most common cyanotic congenital heart disease (CHD) phenotype. Rare genetic variants have been identified as important contributors to the risk of CHD, but relatively small numbers of TOF cases have been studied to date. Here, we use whole exome sequencing to assess the prevalence of rare, potentially deleterious variants in candidate genes previously associated with both syndromic and non-syndromic TOF, in the largest cohort of non-syndromic TOF patients reported to date. Methods & Results 829 non-syndromic TOF patients underwent whole exome sequencing. A systematic review of the literature was conducted which revealed 77 genes in which mutations had been reported in patients with TOF. The presence of rare, deleterious variants in the 77 candidate genes was determined, defined by a minor allele frequency of ≤ 0.001 and scaled combined annotation-dependent depletion (CADD) score of ≥ 20. We found a clustering of heterozygous rare, deleterious variants in NOTCH1 (P=1.89E-15), DOCK6 (P=2.93E-07), MYOM2 (P= 7.35E-05), TTC37 (P=0.016), MESP1 (P=0.024) and TBX1 (P=0.039), after correcting for multiple testing. NOTCH1 was most frequently found to harbour deleterious variants. Changes were observed in 49 patients (6%; 95% confidence interval [CI]: 4.5% - 7.8%) and included six truncating/frameshift variants and forty missense variants. Sanger sequencing of the unaffected parents of thirteen cases identified five de novo variants. Variants were not confined to a single functional domain of the NOTCH1 protein but significant clustering of variants was evident in the EGF-like repeats (P=0.018). Three NOTCH1 missense variants (p.G200R, p.C607Y and de novo p.N1875S) were subjected to functional evaluation and showed a reduction in Jagged1 ligand-induced NOTCH signalling. p.C607Y, which exhibited the most significant reduction in signalling, also perturbed S1 cleavage of the NOTCH1 receptor in the Golgi. Conclusion The NOTCH1 locus is a frequent site of genetic variants predisposing to non-syndromic TOF with 6% of patients exhibiting rare, deleterious variants. Our data supports the polygenic origin of TOF and suggests larger studies may identify additional loci.


Circulation-cardiovascular Genetics | 2013

Association Between C677T Polymorphism of Methylene Tetrahydrofolate Reductase and Congenital Heart DiseaseClinical Perspective

Chrysovalanto Mamasoula; R. Reid Prentice; Tomasz Pierscionek; Faith Pangilinan; James L. Mills; Charlotte M. Druschel; Kenneth A. Pass; Mark W. Russell; Darroch Hall; Ana Töpf; Danielle L. Brown; Diana Zelenika; Jamie Bentham; Catherine Cosgrove; Shoumo Bhattacharya; Javier Granados Riveron; Kerry Setchfield; J. David Brook; Frances A. Bu’Lock; Chris Thornborough; Thahira Rahman; Julian Palomino Doza; Huay Lin Tan; John O’Sullivan; A. Graham Stuart; Gillian M. Blue; David S. Winlaw; Alex V. Postma; Barbara J.M. Mulder; Aelko H. Zwinderman

Background—Association between the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and congenital heart disease (CHD) is contentious. Methods and Results—We compared genotypes between CHD cases and controls and between mothers of CHD cases and controls. We placed our results in context by conducting meta-analyses of previously published studies. Among 5814 cases with primary genotype data and 10 056 controls, there was no evidence of association between MTHFR C677T genotype and CHD risk (odds ratio [OR], 0.96 [95% confidence interval, 0.87–1.07]). A random-effects meta-analysis of all studies (involving 7697 cases and 13 125 controls) suggested the presence of association (OR, 1.25 [95% confidence interval, 1.03–1.51]; P=0.022) but with substantial heterogeneity among contributing studies (I2=64.4%) and evidence of publication bias. Meta-analysis of large studies only (defined by a variance of the log OR <0.05), which together contributed 83% of all cases, yielded no evidence of association (OR, 0.97 [95% confidence interval, 0.91–1.03]) without significant heterogeneity (I2=0). Moreover, meta-analysis of 1781 mothers of CHD cases (829 of whom were genotyped in this study) and 19 861 controls revealed no evidence of association between maternal C677T genotype and risk of CHD in offspring (OR, 1.13 [95% confidence interval, 0.87–1.47]). There was no significant association between MTHFR genotype and CHD risk in large studies from regions with different levels of dietary folate. Conclusions—The MTHFR C677T polymorphism, which directly influences plasma folate levels, is not associated with CHD risk. Publication biases appear to substantially contaminate the literature with regard to this genetic association.


Circulation-cardiovascular Genetics | 2013

Association Between C677T Polymorphism of Methylene Tetrahydrofolate Reductase and Congenital Heart DiseaseClinical Perspective: Meta-Analysis of 7697 Cases and 13 125 Controls

Chrysovalanto Mamasoula; R. Reid Prentice; Tomasz Pierscionek; Faith Pangilinan; James L. Mills; Charlotte M. Druschel; Kenneth A. Pass; Mark W. Russell; Darroch Hall; Ana Töpf; Danielle L. Brown; Diana Zelenika; Jamie Bentham; Catherine Cosgrove; Shoumo Bhattacharya; Javier Granados Riveron; Kerry Setchfield; J. David Brook; Frances A. Bu’Lock; Chris Thornborough; Thahira Rahman; Julian Palomino Doza; Huay Lin Tan; John O’Sullivan; A. Graham Stuart; Gillian M. Blue; David S. Winlaw; Alex V. Postma; Barbara J.M. Mulder; Aelko H. Zwinderman

Background—Association between the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and congenital heart disease (CHD) is contentious. Methods and Results—We compared genotypes between CHD cases and controls and between mothers of CHD cases and controls. We placed our results in context by conducting meta-analyses of previously published studies. Among 5814 cases with primary genotype data and 10 056 controls, there was no evidence of association between MTHFR C677T genotype and CHD risk (odds ratio [OR], 0.96 [95% confidence interval, 0.87–1.07]). A random-effects meta-analysis of all studies (involving 7697 cases and 13 125 controls) suggested the presence of association (OR, 1.25 [95% confidence interval, 1.03–1.51]; P=0.022) but with substantial heterogeneity among contributing studies (I2=64.4%) and evidence of publication bias. Meta-analysis of large studies only (defined by a variance of the log OR <0.05), which together contributed 83% of all cases, yielded no evidence of association (OR, 0.97 [95% confidence interval, 0.91–1.03]) without significant heterogeneity (I2=0). Moreover, meta-analysis of 1781 mothers of CHD cases (829 of whom were genotyped in this study) and 19 861 controls revealed no evidence of association between maternal C677T genotype and risk of CHD in offspring (OR, 1.13 [95% confidence interval, 0.87–1.47]). There was no significant association between MTHFR genotype and CHD risk in large studies from regions with different levels of dietary folate. Conclusions—The MTHFR C677T polymorphism, which directly influences plasma folate levels, is not associated with CHD risk. Publication biases appear to substantially contaminate the literature with regard to this genetic association.

Collaboration


Dive into the Kerry Setchfield's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chris Thornborough

University Hospitals of Leicester NHS Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shoumo Bhattacharya

Wellcome Trust Centre for Human Genetics

View shared research outputs
Top Co-Authors

Avatar

J. David Brook

University of Nottingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gillian M. Blue

Children's Hospital at Westmead

View shared research outputs
Top Co-Authors

Avatar

Jeroen Breckpot

Katholieke Universiteit Leuven

View shared research outputs
Researchain Logo
Decentralizing Knowledge